KR101517626B1 - 감염에 대항하는 후보물질 - Google Patents

감염에 대항하는 후보물질 Download PDF

Info

Publication number
KR101517626B1
KR101517626B1 KR1020097005738A KR20097005738A KR101517626B1 KR 101517626 B1 KR101517626 B1 KR 101517626B1 KR 1020097005738 A KR1020097005738 A KR 1020097005738A KR 20097005738 A KR20097005738 A KR 20097005738A KR 101517626 B1 KR101517626 B1 KR 101517626B1
Authority
KR
South Korea
Prior art keywords
plasminogen
plg
mice
bacterial
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097005738A
Other languages
English (en)
Korean (ko)
Other versions
KR20090059122A (ko
Inventor
토르 뉘
지난 리
융즈 궈
Original Assignee
옴니오 헤아레르 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옴니오 헤아레르 에이비 filed Critical 옴니오 헤아레르 에이비
Publication of KR20090059122A publication Critical patent/KR20090059122A/ko
Application granted granted Critical
Publication of KR101517626B1 publication Critical patent/KR101517626B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
KR1020097005738A 2006-08-28 2007-08-28 감염에 대항하는 후보물질 Expired - Fee Related KR101517626B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82366506P 2006-08-28 2006-08-28
US60/823,665 2006-08-28
PCT/SE2007/050585 WO2008026999A2 (en) 2006-08-28 2007-08-28 Candidates against infection

Publications (2)

Publication Number Publication Date
KR20090059122A KR20090059122A (ko) 2009-06-10
KR101517626B1 true KR101517626B1 (ko) 2015-05-07

Family

ID=39136397

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097005738A Expired - Fee Related KR101517626B1 (ko) 2006-08-28 2007-08-28 감염에 대항하는 후보물질

Country Status (12)

Country Link
US (3) US8318661B2 (https=)
EP (1) EP2056864B1 (https=)
JP (1) JP5566105B2 (https=)
KR (1) KR101517626B1 (https=)
CN (2) CN101563100B (https=)
AU (1) AU2007290881B2 (https=)
CA (1) CA2662101C (https=)
DK (1) DK2056864T3 (https=)
EA (1) EA016250B1 (https=)
ES (1) ES2451015T3 (https=)
MX (1) MX2009002226A (https=)
WO (1) WO2008026999A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
ES2453496T3 (es) 2006-08-28 2014-04-08 Omnio Healer Ab Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
RU2421192C1 (ru) * 2010-03-09 2011-06-20 Винера Гумаровна Нафикова Способ лечения хронического бактериального конъюнктивита
SG187201A1 (en) * 2010-07-26 2013-02-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
EP2661493B1 (en) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
CN102507707B (zh) * 2011-10-12 2015-10-21 山东大学 一种检测龈沟液中蛋白裂解酶含量的方法
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
DK3391902T5 (da) 2015-12-18 2024-09-23 Talengen Int Ltd Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
CA3008475C (en) * 2015-12-18 2024-06-04 Talengen International Limited Method for preventing and treating hepatic tissue injury and related disorders thereof
JP6793748B2 (ja) * 2015-12-18 2020-12-02 タレンゲン インターナショナル リミテッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 放射性および化学的損傷を予防及び治療するための方法
CN106890321A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防和治疗宫颈糜烂的方法
CN108463235A (zh) * 2015-12-18 2018-08-28 泰伦基国际有限公司 一种用于预防和治疗宫颈糜烂的方法
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
CN108463240A (zh) 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法
ES2982294T3 (es) 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
TWI746581B (zh) * 2016-12-15 2021-11-21 大陸商深圳瑞健生命科學硏究院有限公司 纖溶酶原在製備預防和治療脂質腎損傷之藥劑上的用途
JP7213552B2 (ja) * 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
CN108210900A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肥胖症的药物及其用途
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
CN110198732A (zh) * 2016-12-15 2019-09-03 泰伦基国际有限公司 一种促进胰岛素受体底物-2表达的方法
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
JP7242057B2 (ja) * 2016-12-15 2023-03-20 タレンゲン インターナショナル リミテッド 薬物性腎損傷を予防及び治療するための方法
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN107496911A (zh) * 2017-10-20 2017-12-22 滕敏子 一种外科手术后用于防肿胀、抗感染的愈合剂
EP3883598A1 (en) * 2018-11-19 2021-09-29 Nordmark IP GmbH Ancrod for the treatment or prophylaxis of endocarditis
WO2021025043A1 (ja) * 2019-08-07 2021-02-11 学校法人東京歯科大学 判別方法、蛍光測定装置および検査薬
CN111742887A (zh) * 2019-12-19 2020-10-09 广西医科大学第一附属医院 放疗后分泌性中耳炎树鼩模型的建立方法
US20230081922A1 (en) * 2020-02-11 2023-03-16 Talengen International Limited Method and drug for treating viral pneumonia
WO2021180068A1 (zh) * 2020-03-09 2021-09-16 泰伦基国际有限公司 一种治疗2019新型冠状病毒引发疾病的方法和药物
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN115845036B (zh) * 2023-02-20 2023-05-09 滨州益洁口腔有限公司 用于口腔种植体牙龈组织的蛋白酶及制备方法
WO2025017211A1 (en) * 2023-07-20 2025-01-23 Katholieke Universiteit Leuven Treatment of staphylococcal abscesses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020297A2 (en) 2001-09-06 2003-03-13 Omnio Ab Method of improving wound healing
WO2003045466A2 (en) 2001-11-26 2003-06-05 Genentech, Inc. Catheter composition and uses thereof
US20040265968A1 (en) 1997-05-28 2004-12-30 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3023143A (en) * 1959-10-14 1962-02-27 American Cyanamid Co Process for preparing a veterinary composition
AT402367B (de) 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5792835A (en) 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
US5397578A (en) * 1994-03-29 1995-03-14 Tovarischestvo S Ogranichennoi Otvetstvennostiju "Taurus" Method of treatment of chronic purulent inflammations of ear in children
US6420622B1 (en) * 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
JP2003513682A (ja) 1998-07-24 2003-04-15 ファーマカル、バイオテクノロジーズ、インコーポレーテッド 骨組織復元システムおよび方法
AU3862900A (en) 1999-03-01 2000-09-21 Uab Research Foundation Porous tissue scaffolding materials and uses thereof
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
MXPA04007585A (es) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
CN1420126A (zh) 2002-07-10 2003-05-28 牛勃 一种重组人纤溶酶原Kringle5突变体蛋白rhPK－5的制备方法
ES2453496T3 (es) 2006-08-28 2014-04-08 Omnio Healer Ab Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265968A1 (en) 1997-05-28 2004-12-30 Human Genome Sciences, Inc. Tissue plasminogen activator-like protease
WO2003020297A2 (en) 2001-09-06 2003-03-13 Omnio Ab Method of improving wound healing
WO2003045466A2 (en) 2001-11-26 2003-06-05 Genentech, Inc. Catheter composition and uses thereof

Also Published As

Publication number Publication date
CN101573134B (zh) 2013-03-06
CN101573134A (zh) 2009-11-04
US20130149321A1 (en) 2013-06-13
EP2056864B1 (en) 2013-12-11
JP2010502600A (ja) 2010-01-28
WO2008026999A2 (en) 2008-03-06
US8318661B2 (en) 2012-11-27
AU2007290881A1 (en) 2008-03-06
DK2056864T3 (en) 2014-03-10
EA016250B1 (ru) 2012-03-30
US20100099600A1 (en) 2010-04-22
KR20090059122A (ko) 2009-06-10
EA200970233A1 (ru) 2009-08-28
EP2056864A2 (en) 2009-05-13
CN101563100B (zh) 2013-08-07
CA2662101C (en) 2015-07-07
WO2008026999A3 (en) 2008-05-22
MX2009002226A (es) 2009-09-07
US10729750B2 (en) 2020-08-04
ES2451015T3 (es) 2014-03-26
AU2007290881B2 (en) 2013-03-07
CA2662101A1 (en) 2008-03-06
US20160243204A1 (en) 2016-08-25
CN101563100A (zh) 2009-10-21
EP2056864A4 (en) 2012-01-25
JP5566105B2 (ja) 2014-08-06

Similar Documents

Publication Publication Date Title
KR101517626B1 (ko) 감염에 대항하는 후보물질
Hayashida et al. Molecular and cellular mechanisms of ectodomain shedding
Gasse et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis
CN1961958B (zh) 改善伤口愈合的方法
Zhang et al. Evaluation of breviscapine on prevention of experimentally induced abdominal adhesions in rats
AU2023208109B2 (en) Novel therapy
JP2020023519A (ja) 異常な皮膚瘢痕化の治療
Gabre et al. Activated protein C accelerates venous thrombus resolution through heme oxygenase‐1 induction
JP2020186263A (ja) 放射性および化学的損傷を予防及び治療するための方法
Homma et al. Potential involvement of the epidermal growth factor receptor ligand epiregulin and matrix metalloproteinase-1 in pathogenesis of chronic rhinosinusitis
Puliti et al. Contribution of matrix metalloproteinase 2 to joint destruction in group B Streptococcus–induced murine arthritis
JP5576657B2 (ja) カスパーゼ−８ならびに炎症、感染および創傷治癒
KR101976633B1 (ko) 폐 섬유증의 예방 또는 치료용 약학적 조성물
KR20140004620A (ko) 초기 면역 방어에 있어서 신규한 기능을 발휘하는 선구 세린 프로테아제 응고 캐스케이드
HK1136204A (en) Candidates against infection
CN101541829A (zh) 来自丝光绿蝇的胰凝乳蛋白酶及其在治疗伤口中的用途
Bunnett et al. Protease-activated receptors in gastrointestinal function and disease
Wernersson Mast Cell Proteases

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180406

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190416

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200429

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200429